Trial Profile
The effect of empagliflozin on diuresis and neurohumoral factors in the patients with decompensated heart failure and diabetes mellitus: pilot study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Nov 2022
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Heart failure; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EmpaHF-P
- 30 Jul 2017 Status changed from not yet recruiting to recruiting.
- 24 May 2017 New trial record